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Abstract
Background
There is currently no consensus regarding the optimal number of chemotherapy cycles to
be administered before and after interval debulking surgery (IDS) in patients with advanced
ovarian cancer. This study aimed to evaluate the impact of the number of neoadjuvant che-
motherapy (NAC) and postoperative adjuvant chemotherapy (POAC) cycles on the survival
of patients with advanced ovarian cancer undergoing NAC/IDS/POAC.
Methods
We retrospectively reviewed data from 203 patients who underwent NAC/IDS/POAC at
Yonsei Cancer Hospital between 2006 and 2016. All patients underwent taxane plus carbo-
platin chemotherapy for NAC and POAC. The patient outcomes were analyzed according to
the number of NAC, POAC, and total chemotherapy (NAC+POAC) cycles.
Results
Patients who received fewer than 6 cycles of total chemotherapy (n = 8) had poorer progres-
sion-free survival (PFS) and overall survival (OS) than those completing at least 6 cycles
(p = 0.005 and p<0.001, respectively). Among patients who completed at least 6 cycles
of total chemotherapy (n = 189), Kaplan-Meier analysis revealed no significant difference
in either PFS or OS according to the number of NAC cycles (1–3 vs.4; p = 0.136 and
p = 0.267, respectively). Among patients who experienced complete remission after 3 cycles
of POAC (n = 98), the addition of further POAC cycles did not improve the PFS or OS (3 vs.
4; p = 0.641 and p = 0.104, respectively).
Conclusion
IDS after 4 cycles of NAC may be a safe and effective option when completing 6 cycles of
total chemotherapy. Furthermore, the addition of more than 3 cycles of POAC does not
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appear to influence the survival of patients achieving completion remission after 3 cycles of
POAC.
Introduction
Ovarian cancer is the second most common gynecologic cancer in Korea; each year, its inci-
dence and mortality are continuously increasing by 1.5% and 6.2%, respectively [1,2]. The
standard treatment for advanced ovarian cancer consists of optimal cytoreductive surgery fol-
lowed by taxane and platinum-based adjuvant chemotherapy [3]. Neoadjuvant chemotherapy
(NAC) and interval debulking surgery (IDS) have been proposed as alternatives for the man-
agement of advanced ovarian cancer patients unable to undergo complete debulking during
primary surgery [4–6].
Four randomized clinical trials demonstrated that NAC/IDS is not inferior to primary
debulking surgery (PDS) for the treatment of advanced ovarian cancer [7–10]. In the European
Organization for Research and Treatment of Cancer (EORTC) 55971 trial, patients received 3
cycles of NAC followed by IDS and at least 3 cycles of postoperative adjuvant chemotherapy
(POAC) [7]. In the CHORUS trial, patients in the NAC arm underwent 3 cycles of NAC fol-
lowed by IDS and 3 cycles of POAC [8]. In the SCORPION trial, patients were received 3 or 4
cycles of NAC and then POAC administered after IDS to complete 6 cycles of total chemother-
apy [9]. In the JCOG 0602 trial, patients treated 4 cycles of NAC followed by IDS and 4 cycles
of POAC [10].
The National Comprehensive Cancer Network (NCCN) guidelines recommend at least a
total of 6 cycles of chemotherapy for suspected cases of unresectable advanced-stage ovarian
cancer, as well as IDS prior to the fourth cycle of NAC [11]. However, the optimal number of
chemotherapy cycles before and after IDS has not been prospectively evaluated, and various
clinical regimens are currently utilized based on the patient condition and physician prefer-
ence. Several studies have demonstrated the safety and feasibility of late IDS, defined as IDS
performed after more than 4 cycles of NAC [12–14], whereas others have reported poorer out-
comes in patients undergoing late IDS [15,16]. Furthermore, there is currently no evidence
that additional chemotherapy of more than 6 cycles of first-line chemotherapy improves out-
comes in patients with advanced-stage ovarian cancer [17]. Therefore, the aim of the present
study was to evaluate the impact of the number of NAC and POAC cycles on survival in
advanced-stage ovarian cancer patients undergoing NAC followed by IDS and POAC.
Materials and methods
We conducted a retrospective analysis of the medical records of 203 patients with patholog-
ically confirmed epithelial ovarian cancer who received NAC at Yonsei Cancer Hospital
between 2006 and 2016. The present study was reviewed and approved by the Institutional
Review Board of Severance Hospital at Yonsei University College of Medicine (Registration
number: 4-2015-1158) and the need for informed consent was waived. The patient records
were anonymized and de-identified prior to analysis.
The inclusion criteria were as follows: (1) pathological diagnosis of International Federation
of Gynecology and Obstetrics (FIGO) stage III or IV epithelial ovarian cancer and (2) treat-
ment with at least 1 cycle of NAC followed by IDS. Four patients with FIGO stage I or II
ovarian cancer and 2 patients who refused to undergo IDS after NAC were excluded. The
remaining 197 patients were included in the final analysis. All surgical procedures were
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performed by one of five gynecologic oncology surgeons at Yonsei Cancer Hospital, and
pathology review was performed by two pathologists at the same institution.
Patients were clinically diagnosed with FIGO stage III or IV by initial imaging workup,
comprising abdominal and pelvic computed tomography (CT) and 18F-fluorodeoxyglucose-
positron emission tomography/CT. The diagnoses were histologically confirmed by examina-
tion of the biopsy specimens removed during diagnostic laparoscopy, or by cytological assess-
ment of ascites or pleural effusion. Our institution applied the following principle for the
primary treatment strategy: NAC was performed if at least one of the following three criteria
was met: 1) pulmonary and/or hepatic parenchymal metastases were observed on imaging
studies, 2) the tumors were medically inoperable, and/or 3) optimal cytoreduction was unsuit-
able due to a high tumor burden (Fagotti score > 8).
Data regarding the patients’ age and body mass index, the FIGO stage, histology, American
Society of Anesthesiologists score, preoperative serum cancer antigen-125 level, residual dis-
ease after IDS, performance of radical surgery, and number of total chemotherapy, NAC, and
POAC cycles were extracted from the patient medical records. All patients received combina-
tion chemotherapy with taxane and carboplatin. Conventional surgery included total hysterec-
tomy, bilateral salpingo-oophorectomy, infracolic omentectomy, pelvic/para-aortic lymph
node dissection, and appendectomy. Radical surgery was defined as operations involving radi-
cal oophorectomy, bowel resection, diaphragm or other peritoneal surface stripping, splenec-
tomy, partial hepatectomy, partial gastrectomy, or partial cystectomy and/or
ureteroneocystostomy, cholecystectomy, and/or distal pancreatectomy [18–20]. CT images
were obtained prior to IDS and after 3 cycles of POAC to evaluate the patient responses to
treatment. Objective responses were determined based on the Response Evaluation Criteria in
Solid Tumors (RECIST) [21]. Survival outcomes were analyzed according to the number of
total chemotherapy (NAC+POAC; <6 vs. 6 vs.7), NAC (1–3 vs.4), and POAC (3 vs.4)
cycles.
Overall survival (OS) was defined as the time from the date of first chemotherapy to the
date of death. Progression-free survival (PFS) was defined as the time from the date of first che-
motherapy to the date of first recurrence. The treatment-free interval (TFI) was defined as the
interval from the end of platinum-based chemotherapy to the first recurrence.
Statistical analysis
SPSS version 18 for Windows (SPSS, Inc., Chicago, IL, USA) was used for all statistical analy-
ses. Survival curves were constructed using the Kaplan-Meier method, with the log-rank test
applied to detect differences between the groups. Multivariate analyses for OS and PFS were
performed using Cox regression models. We investigated the linear trends in the number of
NAC/POAC cycles using the chi-square test. For all analyses, the level of statistical significance
was set at p< 0.05.
Results
A total of 197 patients with pathologically confirmed FIGO stage III or IV epithelial ovarian
cancer underwent at least 1 cycle of NAC followed by IDS at our institution during the study
period. The baseline characteristics of all patients are detailed in Table 1. The median patient
age was 57 years (range: 27–80 years). We confirmed the diagnosis histologically by diagnostic
laparoscopy in 119 (60.4%), by cytology of ascites in 56 (28.4%) or pleural effusion in 22
(11.2%) before starting chemotherapy. The percentage of patients with FIGO stage IV ovarian
cancer at the time of diagnosis was 73.6%. To achieve maximum cytoreduction, 84 (42.64%)
patients underwent at least one radical surgery, including bowel surgery at the time of IDS in
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Table 1. Baseline patient characteristics (n = 197).
Variables
Median age, years (range) 57 (27–80)
ASA score, n (%)
1 51 (26.3)
2 92 (47.4)
3 50 (25.8)
4 1 (0.5)
Not available 3 (1.5)
Median BMI at diagnosis, kg/m2 (range) 22.83 (16.38–35.84)
Median CA 125 level at diagnosis, U/mL (range) 1825.7 (44.3–30000)
FIGO stage, n (%)
IIIB 7 (3.6)
IIIC 45 (22.8)
IVA 89 (45.2)
IVB 56 (28.4)
Histologic type, n (%)
Serous 180 (91.4)
Mucinous 4 (2.0)
Endometrioid 3 (1.5)
Clear cell 7 (3.6)
Others 3 (1.5)
Radical surgery, n (%)
None 113 (57.36)
Bowel surgery 30 (15.23)
VATS 29 (14.72)
Splenectomy 25 (12.69)
Liver resection 17 (8.63)
SCF resection 4 (2.03)
Breast/axillar LN dissection 6 (3.05)
Ureter resection 4 (2.03)
Others 14 (7.11)
Methods of biopsy, n (%)
Diagnostic laparoscopy 119 (60.4)
Ascites 56 (28.4)
Pleural effusion 22 (11.2)
Residual disease after IDS, n (%)
NGR 72 (36.6)
0.5 cm 63 (32.0)
1 cm 27 (13.7)
2 5 (2.5)
>2 8 (4.1)
Unknown 22 (11.2)
Cycles of NAC, median (range) 3 (1–9)
Number of NAC cycles, n (%)
<4 152 (77.2)
4 45 (22.8)
Cycles of POAC, median (range) 5 (0–9)
Number of POAC cycles, n (%)
(Continued )
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30 patients (15.23%). The percentage of patients with no gross residual disease following cytor-
eduction was 36.6%. The median number of total chemotherapy cycles (NAC+POAC) was 8
(range: 3–12), while the median number of NAC cycles was 3 (range: 1–9), and the median
number of POAC cycles was 5 (range: 0–9). All patients received first-line taxane plus plati-
num combination chemotherapy as NAC and POAC. After NAC, most patients (n = 160,
81.2%) exhibited a partial response, and 98 (49.7%) patients exhibited a complete response
after 3 cycles of POAC.
The median follow-up was 26.7 months (range: 3.0–101.8 months), during which there
were 131 recurrences and 71 deaths. Eight patients underwent<6 cycles of total chemotherapy
(NAC+POAC); the reasons for discontinuation in these patients are shown in Table 2.
Compared to patients receiving 6 and7 cycles of total chemotherapy, patients who
received<6 cycles (n = 8) showed worse PFS and OS (p = 0.005 and p<0.001, respectively)
(S1 Fig). Based on this finding, we next analyzed the correlation between the number of NAC/
POAC cycles and clinical outcomes in patients who completed at least 6 cycles of total chemo-
therapy. Among patients who underwent at least 6 cycles of total chemotherapy, Kaplan-Meier
curve and log-rank analyses revealed no significant difference in either PFS or OS between
patients undergoing IDS after 1–3 vs.4 cycles of NAC (p = 0.136 and p = 0.267, respectively)
(Fig 1). After 3 cycles of POAC, 98 patients experienced complete remission, as determined by
CT. Among these patients, the use of more than 3 cycles of POAC did not significantly
improve the PFS or OS (3 vs.4 cycles, p = 0.641 and p = 0.104, respectively; Fig 2). Overall,
the results were consistent when we performed subgroup analysis for patients with high-grade
serous carcinoma (HGSC) (S2–S4 Figs). When we performed sensitivity analysis in patients
who completed 6 cycles and 9 cycles of total chemotherapy, there was no significant difference
in either PFS or OS between patients undergoing IDS after 1–3 vs.4 cycles of NAC in
patients (S5 and S6 Figs). In addition, when we confined to patients who underwent 3 cycles of
Table 1. (Continued)
Variables
<4 83 (42.1)
4 114 (57.9)
Cycles of total chemotherapy (NAC+POAC), median (range) 8 (3–12)
Number of total chemotherapy (NAC+POAC), n (%)
<6 8 (4.1)
6 189 (95.9)
ASA, American Society of Anesthesiologists; BMI, body mass index; CA 125, cancer antigen 125; FIGO,
Federation of Gynecology and Obstetrics; VATS, video-assisted thoracoscopic surgery; SCF,
supraclavicular fossa; LN, lymph node; NGR, no gross residual disease; NAC, neoadjuvant chemotherapy;
POAC, postoperative adjuvant chemotherapy
https://doi.org/10.1371/journal.pone.0183754.t001
Table 2. Reasons for not completing 6 cycles of total chemotherapy (n = 8).
n (%)
Progression of disease 3 (37.5)
Poor general condition 2 (25.0)
Death 2 (25.0)
Follow up loss 1 (12.5)
https://doi.org/10.1371/journal.pone.0183754.t002
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NAC, the additional of more than 3 cycles of POAC did not significantly improve the outcome
(S7 Fig).
Next, we evaluated the relationship between the median TFI and the number of NAC cycles
before IDS to determine the optimal timing of IDS (Fig 3A). We also evaluated the correlation
between the median TFI and the number of POAC cycles in patients with complete remission
after 3 cycles of POAC to determine the most appropriate number of POAC cycles (Fig 3B).
No significant correlation was observed between the risk of recurrence and the number of
NAC cycles before IDS or the number of POAC cycles in patients with complete remission
after 3 cycles of POAC (p for trend = 0.386 and 0.215, respectively).
Multivariate analyses revealed a significant effect of the number of total chemotherapy
cycles (NAC+POAC) on both PFS (hazard ratio 0.36; 95% confidence interval, 0.15–0.84) and
OS (hazard ratio, 0.09; 95% confidence interval, 0.03–0.26) in patients who had undergone at
least 6 cycles (S1 Table). However, among these patients, neither the number of NAC cycles
nor POAC cycles influenced the PFS or OS (S2 Table).
Fig 1. Kaplan-Meier survival curves for patients undergoing at least 6 cycles of total chemotherapy.
(A) Progression-free survival and (B) overall survival according to the number of NAC cycles (<4 vs.4).
NAC: neoadjuvant chemotherapy.
https://doi.org/10.1371/journal.pone.0183754.g001
Fig 2. Kaplan-Meier survival curves for patients who attained complete remission after 3 cycles of
POAC and underwent at least 6 cycles of total chemotherapy. (A) Progression-free survival and (B)
overall survival according to the number of additional POAC cycles (3 vs.4). POAC: postoperative adjuvant
chemotherapy.
https://doi.org/10.1371/journal.pone.0183754.g002
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Discussion
In the present study, we aimed to evaluate the association between the number of NAC/
POAC/total chemotherapy cycles and clinical outcomes in patients with advanced ovarian
cancer. Our findings suggest that completion of at least 6 cycles of total chemotherapy is an
independent prognostic factor in patients undergoing NAC/IDS/POAC. However, the pre-
scription of more than 3 cycles of NAC or POAC did not significantly improve the patient sur-
vival further.
The ideal time for cytoreductive surgery in patients undergoing NAC/IDS remains contro-
versial. The NCCN guidelines recommend IDS prior to the fourth cycle of NAC. The evidence
for 3 cycles of NAC is based on the findings of two randomized controlled trials, which dem-
onstrated that such treatment was equivalent in efficacy to PDS [7,8]. The protocols of these
two trials specified that IDS should be performed after 3 cycles of NAC. Other recent studies
have reported conflicting results for performing late IDS after >4 cycles of NAC in patients
with advanced ovarian cancer [12–16]. In one previous study, IDS after >6 cycles of NAC was
found to be both safe and effective, with outcomes equivalent to those reported for the stan-
dard treatment [13]. Akladios et al. reported that the number of NAC cycles did not affect the
survival of advanced-stage ovarian cancer patients [12], while Colombo et al. reported that
patients who received>4 cycles of NAC before IDS experienced poor prognosis, despite
Fig 3. Linear trends analyses for the median TFI as the number of NAC/POAC cycles increases. The
tendency of the median TFI according to (A) the timing of interval debulking surgery and (B) the number of
POAC cycles in patients with complete remission after 3 cycles. TFI: treatment-free interval; NAC:
neoadjuvant chemotherapy; POAC: postoperative adjuvant chemotherapy.
https://doi.org/10.1371/journal.pone.0183754.g003
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optimal debulking surgery. Similarly, Xu et al. reported that patients who underwent >5 cycles
of NAC experienced shorter PFS than patients who underwent <5 cycles [16].
The appropriate number of POAC cycles after IDS also remains controversial. Although
3–6 cycles of POAC are typically administered, various protocols are utilized based on the
patient’s condition and physician preference. The EORTC trial recommended at least 3 cycles
of POAC after IDS [7], whereas the CHORUS and SUNNY trials specified that precisely 3
cycles of POAC should be administered after IDS [8]. There is limited evidence suggesting that
the addition of>3 cycles of POAC after IDS improves outcomes in patients with advanced-
stage ovarian cancer. Xu et al. reported that patients who underwent<5 cycles of adjuvant
chemotherapy after IDS experienced shorter PFS and OS than patients who underwent >5
cycles of adjuvant chemotherapy after IDS [16]. Prolonged cycles of POAC may be useful in
patients with residual tumors or an incomplete response after 3 cycles of POAC. Therefore, in
the present study, we analyzed the outcomes in a subgroup of patients who achieved complete
radiological remission after 3 cycles of POAC. However, our analysis revealed no benefit of
additional POAC cycles.
Our study has several implications. Our findings suggest that patients with advanced ovar-
ian cancer should be treated with at least 6 cycles of total chemotherapy (NAC+POAC).
Indeed, we observed that patients treated with<6 cycles of total chemotherapy experienced
poorer PFS and OS than those treated with6 cycles of total chemotherapy. These findings
suggest the importance of adhering to the current guidelines, which recommend the use of at
least 6 cycles of total chemotherapy for the treatment of advanced-stage ovarian cancer [22].
We further observed that the number of NAC cycles did not influence the survival of the
patients, suggesting that the neoadjuvant approach with late IDS is safe and effective for
patients who are unable to undergo complete debulking surgery. Indeed, we observed similar
survival outcomes for this approach and IDS after 3 cycles of NAC. Furthermore, the addition
of>3 POAC cycles after IDS did not improve the PFS and OS in patients who had achieved
complete radiological remission after 3 cycles of POAC. It is important to note that additional
cycles not only increase the cost of treatment, but also increase the risk of toxicity and plati-
num resistance due to prolonged chemotherapy. In a previous study involving patients who
had achieved complete remission after PDS plus 6 cycles of chemotherapy, the addition of 3
cycles of consolidation chemotherapy did not improve survival outcomes, although increased
toxicity was observed [23]. Similarly, addition of>3 cycles of POAC did not improve the sur-
vival outcomes in patients achieving complete remission after NAC/IDS plus 3 cycles of
POAC in the present study. Therefore, additional maintenance chemotherapy should be
regarded as an optional, rather than a necessary, treatment strategy, as determined based on
the individual patient’s condition [23–26].
The present study also possesses several limitations. First, as this was a retrospective study,
selection bias was inevitable and may have influenced our results. Especially, the timing of
IDS was decided at the treating physician’s discretion. After each cycle of NAC, each gyneco-
logic oncologist evaluated the patient’s status and recommended further NAC in individuals
who were not suitable for complete debulking and still exhibited a poor response. Second,
with the increased use of NAC in recent years, our cohort is limited by the short follow-up
period. Further studies to obtain long-term follow-up data on the PFS and OS rates are
needed.
In conclusion, our findings indicate that completion of at least 6 cycles of total chemother-
apy is an independent prognostic factor in patients undergoing NAC/IDS/POAC. Although
such treatment is currently recommended, we observed that the addition of more than 3 NAC
or POAC cycles did not affect the patient survival. Therefore, IDS after more than 4 cycles of
NAC may be a safe and effective option for patients unable to undergo optimal cytoreduction.
Chemotherapy cycles in advanced-ovarian cancer
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Furthermore, our findings indicate that additional POAC cycles may not be necessary when
complete remission is achieved after 3 cycles of POAC.
Supporting information
S1 Fig. Kaplan-Meier survival curves. (A) Progression-free survival and (B) overall survival
according to the number of total (NAC+POAC) chemotherapy cycles (<6 vs. 6 vs.7). NAC:
neoadjuvant chemotherapy; POAC: postoperative adjuvant chemotherapy.
(TIF)
S2 Fig. Kaplan-Meier survival curves for patients with HGSC. (A) Progression-free survival
and (B) overall survival according to the number of total (NAC+POAC) chemotherapy cycles
(<6 vs. 6 vs.7). NAC: neoadjuvant chemotherapy; POAC: postoperative adjuvant chemo-
therapy; HGSC: high-grade serous carcinoma.
(TIF)
S3 Fig. Kaplan-Meier survival curves for patients undergoing at least 6 cycles of total che-
motherapy with HGSC. (A) Progression-free survival and (B) overall survival according to
the number of NAC cycles (<4 vs.4). NAC: neoadjuvant chemotherapy; HGSC: high-grade
serous carcinoma.
(TIF)
S4 Fig. Kaplan-Meier survival curves for patients who attained complete remission after 3
cycles of POAC and underwent at least 6 cycles of total chemotherapy with HGSC. (A) Pro-
gression-free survival and (B) overall survival according to the number of additional POAC
cycles (3 vs.4). POAC: postoperative adjuvant chemotherapy; HGSC: high-grade serous car-
cinoma.
(TIF)
S5 Fig. Sensitivity analysis in subgroup of patients who completed 6 cycles of total chemo-
therapy. (A) Progression-free survival and (B) overall survival according to the number of
NAC cycles (<4 vs.4). NAC: neoadjuvant chemotherapy.
(TIF)
S6 Fig. Sensitivity analysis in subgroup of patients who completed 9 cycles of total chemo-
therapy. (A) Progression-free survival and (B) overall survival according to the number of
NAC cycles (<4 vs.4). NAC: neoadjuvant chemotherapy.
(TIF)
S7 Fig. Kaplan-Meier survival curves for patients underwent 3 cycles of NAC and at least 6
cycles of total chemotherapy when complete remission was achieved after 3 cycles of
POAC. (A) Progression-free survival and (B) overall survival according to the number of addi-
tional POAC cycles (3 vs.4). NAC: neoadjuvant chemotherapy; POAC: postoperative adju-
vant chemotherapy.
(TIF)
S1 Table. Univariate and multivariate analyses for progression-free survival and overall
survival.
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S2 Table. Univariate and multivariate analyses for progression-free survival and overall
survival in patients undergoing at least 6 cycles of total chemotherapy.
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